Press Releases

Wendy Buckland to Join Emmes as Chief Operating Officer

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Aptevo's APVO436 was found to show a clinical benefit in a Phase 1 study as part of a combination therapy with venetoclax and azacitidine

Global Clinical Trials Connect 2023

“Collaboration, Innovation and Enhancing Quality in Clinical Trials”Conference, Expo and Workshop

Global Pharmaceutical Company Merz Choose Generis’ CARA Life Sciences Platform to Consolidate their R&D Content

Generis has announced that Merz has selected Generis' CARA™ Life Sciences Platform for managing all the documents in their R&D process.

HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

Integrated Synthesis-to-Clinic® Program Will Support HTD1801’s Clinical Development and Regulatory Submission Package

Lifeasible Released an Exclusive Qualitative and Quantitative Pollen Composition Analysis Service

Creative Biostructure Supports Bacteriophage Research with iEM Platform

ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported interim clinical outcomes from the first ten[1] people treated to regulate blood pressure with implantable ARC Therapy, ONWARD’s targeted spinal cord stimulation technique. ARC Therapy immediately improved blood pressure levels for all participants; this benefit has been sustained for the duration of the current follow-up period. Participants have also reported improved quality of life, increased energy and vitality, and reduced dizziness.

OVER £175 MILLION FOR CUTTING-EDGE GENOMICS RESEARCH TO HELP BOOST DIAGNOSIS AND TREATMENT FOR PATIENTS

Genomics England has announced funding of £105 million to kickstart a world-leading research study, in partnership with the NHS, to explore the effectiveness of using whole genome sequencing to find and treat rare genetic diseases in newborn babies.

Three Featured Products Upgraded at Alfa Chemistry: Protection Reagents, Environmental Goods Standards, Porphyrins and Phthalocyanines

On the occasion of Thanksgiving and Christmas, Alfa Chemistry would like to express its sincere gratitude to its global customers. In addition to discounts and exquisite gifts offered to ordering customers, the company also continuously improves its product lines. Fairly recently, Alfa Chemistry announced the upgrade of its featured products, i.e., protection reagents, environmental goods standards, as well as porphyrins and phthalocyanines, supporting better user experience and wider choices for customers across the world.

CD Formulation Launches One-stop OEM/ODM and Analytical Testing Solutions for Cosmetics

The past decade has seen exponential growth of the cosmeceutical market in the personal care industry. There is increasing use of alpha hydroxy acids for skin rejuvenation as well as the use of vitamin C in topical formulations as an antioxidant. In response to such a trend, CD Formulation recently launched one-stop OEM/ODM and analytical testing solutions for cosmetic formulations.

Curebase Releases Diagnostic Offering that Delivers First All-Inclusive Package of Software and Services Needed to Fully Execute Diagnostic Studies

Start-up trials achieved in eight to 12 weeks, a fraction of typical timeframe

InsightRX Provides Máxima Medical Center with Precision Dosing Guidance

Large teaching hospital in the Netherlands relies on precision dosing platform for point-of-care decision support and immunology research

CluePoints Appoints Andy Cooper as New Chief Executive Officer

CluePoints Appoints Andy Cooper as New Chief Executive Officer New CEO brings a combination of experience and drive as CluePoints rapidly scales its RBQM and Data Quality Oversight offerings

MultiCare Partners with IllumiCare to Offer Clinical Trials at Point-of-Care with Trials App

MultiCare Health System is the first to use the Illumicare Trials App in a clinical setting, streamlining clinical trial recruitment and increasing awareness among providers, patients and clinical research teams.

Digital Therapeutics Alliance and Curebase release publication setting the stage for a fit-for-purpose evidence standard for digital therapeutics (DTx)

Digital Therapeutics Alliance and Curebase release publication setting the stage for a fit-for-purpose evidence standard for digital therapeutics (DTx)

Tesis Biosciences Announces Proposed Study of Veterans and Civilians with Mild Traumatic Brain Injury

Tesis Biosciences Announces Proposed Study of Veterans and Civilians with Mild Traumatic Brain Injury - Company in preparation for formal FDA approval submission

International Organization for Standardization Publishes Revisions to ISO 15189

International Organization for Standardization publishes revisions to ISO 15189.

Emmes Launches Cell and Gene Therapy Center

PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations

PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations London, UK and Durham, NC – 08 December, 2022 – PHASTAR, a global specialist biometrics contract research organization (CRO), has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.